Skip to main content

Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefit–hazard ratio

Buy Article:

$43.00 plus tax (Refund Policy)

Abstract Background: 

Medical patients may benefit from anticoagulant prophylaxis of venous thromboembolism (VTE), but assessment of thrombotic risk is complex. I describe a method for estimating the minimum thrombotic risk required to ensure that a reasonable benefit–hazard ratio is maintained. Methods: 

An equation was derived relating baseline VTE risk and a minimum acceptable benefit–hazard ratio (R), defined as ‘pulmonary embolus (PE) alone’, ‘PE or symptomatic proximal deep venous thrombosis (DVT)’, or ‘PE or any symptomatic DVT’ prevented per major bleeding. The equation was used to estimate the relative risk (RR) of thromboembolism required for net benefit (main outcome measure). The PREVENT study was the primary data source, backed by data from two meta-analyses. Results: 

For R ranging from 3 to 10, the RR required for net beneficial prophylaxis was 6.5–21.6 (PE alone); 3.0–9.9 (PE or symptomatic proximal DVT); and 2.3–7.6 (PE or any symptomatic DVT), respectively. These RR are possible only in the presence of risk factors of high weighting. Sensitivity analysis showed that the findings were robust to changes in baseline assumptions related to thrombosis and bleeding rates. Conclusion: 

A method for risk assessment for medical thromboprophylaxis has been developed. The results suggest that only a minority of medical patients with high RR should receive prophylaxis.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: benefit–harm ratio; low molecular weight heparin; major bleeding; thromboprophylaxis; treatment guideline; venous thromboembolism

Document Type: Research Article

Publication date: 2009-09-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more